Enterprise Europe Network

A Japanese compound screening company for drug discovery offers its services to EU pharmaceutical and biotech companies

Country of origin:
Country: 
JAPAN
Opportunity:
External Id: 
BOJP20171110001
Published
10/11/2017
Last update
20/11/2018
Expiration date
26/11/2019

Keywords

Partner keyword: 
Cellular and Molecular Biology
Stem cells and biobanks
Pharmaceuticals/fine chemicals
Agro and Marine biotech
Research and experimental development on biotechnology
EXPRESS YOUR INTEREST

Summary

Summary: 
The Japanese company provides compound screening services for the discovery of small molecular drugs and target protein identification services. Strong in a database of one million diversified compounds and with advanced technology and expertise, the company targets pharmaceutical and biotech companies of any size with whom to achieve a service partnership agreement.

Description

Description: 

The Japanese company provides compound screening services for the discovery of small molecular drugs and target protein identification services. The ideal partners are EU pharmaceutical and biotech companies of any size in need of such type of services.

Small and medium sized pharmaceutical companies and biotech companies prefer to outsource their screening activities as they lack of in-house capabilities, while for large companies, even though in-house capabilities exist in their structures, they are insufficient to meet all their drug discovery needs especially for screening diversified compound libraries and specialized targets.

To solve above issues, the Japanese company has access to a library of one million diversified compounds with therefore more advanced expertise compared to similar service providers.

They are capable of:
- screening for targets that cannot be handled by conventional screening methods;
- screening for a backup target without extra charge if there is no hit for the priority target;
- targeting protein identification for unknown compounds.

The EU market structure is basically the same as the Japanese one, but thanks to the fact that the number of pharmaceutical and biotech companies is a lot higher than in Japan, the company is expecting further business opportunities in accessing it.

The company wishes to do business in a direct sales method in EU countries targeting pharmaceutical and biotech organizations to establish cooperation in terms of services agreement.

Since screening services offered by the company are consistently required in drug discoveries' processes, longer term partnerships are expected from this offer.

Advantages & innovations

Cooperation plus value: 
Number of suppliers for this type of services is quite limited despite the high demand from pharma & biotech sectors. What makes the Japanese company stand out among others is resumed here and refer to its expertise and technology: - A library of one million diversified compounds - The company provides target protein identification services for target unknown compounds. Advantages are that there is no need to label compounds, while it is still necessary for conventional methods, and that even membrane proteins and low-expressed proteins in the cells can be detected; this is almost impossible with conventional screening methods. This method is useful for target identification of compounds from phenotypic screening and re-positioning of drugs - They can do target protein identification of more than 100 compounds at the same time whilst the common average of identifiable compounds is approximately of 10 or less - They also have a screening technology for the discovery of small molecular drugs and it can be applied to every target. It is especially applied to targets such as orphan receptors that it is difficult to develop assays, and some ion channels and transporters that it is difficult to achieve high throughput. Though it is common to do screenings simultaneously for 4-5 targets, they are able to do so for tens of targets - Their technology can be applied not only for screening of individual targets, but also for prioritizing targets from multiple candidate targets. It enables to determine promising targets from multiple ones in the pathway - They are building a database of hit compounds (binders) for thousands of targets at the same time - Despite success rate of small molecular drug discovery research continues to drop, their screening technology of High Throughput Screening would help increase accuracy to pursue possibilities of small molecule compounds such as Solute carrier (SLC) transporters, Orphan G protein-coupled receptors -GPCRs

Partner sought

Cooperation area: 
The partners sought are pharmaceutical and/or biotechnology companies of any size that conduct in house drug discovery, that wish to improve compound screening process and that are looking for a reliable partner able to provide them a high level of expertise in new technologies and analysis.

Type and size

Cooperation task: 
SME 11-50,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500

Dissemination

Dissemination sector group : 
Dissemination preferred : 
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom